Characteristics of Memory B Cells Elicited by a Highly Efficacious HPV Vaccine in Subjects with No Pre-existing Immunity

PLoS Pathogens

Volumn 10, Issue 10, 2014, Pages

  Scherer, Erin M ^a   Smith, Robin A ^a   Simonich, Cassandra A ^a,b,c   Niyonzima, Nixon ^a,c,d   Carter, Joseph J ^a   Galloway, Denise A ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UGANDA CANCER INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; CELL ISOLATION; CELL SELECTION; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; INFLUENZA; INNATE IMMUNITY; MEMORY CELL; MOLECULAR CLONING; NEUTRALIZATION ASSAY; PATHOGENESIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEQUENCE ANALYSIS; VACCINATION; VIRUS NEUTRALIZATION; B LYMPHOCYTE; COMMUNICABLE DISEASE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PROCEDURES; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADOLESCENT; B-LYMPHOCYTES; COMMUNICABLE DISEASES; FEMALE; HIV INFECTIONS; HIV-1; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOLOGIC MEMORY; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84908329318     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004461     Document Type: Article

References (70)

1. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102: 325–339.
2. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, JrPenny ME, et al. (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364: 401–411.
3. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, JrAranda C, et al. (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365: 1576–1585.
4. Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA, (2012) Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 30 Suppl 5: F1–11.
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. The New England journal of medicine 356: 1928–1943.
6. The Future II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England journal of medicine 356: 1915–1927.
7. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26: 6844–6851.
8. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, et al. (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69: 3959–3963.
9. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, et al. (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8: 260–270.
10. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92: 11553–11557.
11. Plotkin SA, (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47: 401–409.
12. Victora GD, Nussenzweig MC, (2012) Germinal centers. Annu Rev Immunol 30: 429–457.
13. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466.
14. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, et al. (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25: 4931–4939.
15. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, et al. (2011) Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum Vaccin 7: 1343–1358.
16. Doucett VP, Gerhard W, Owler K, Curry D, Brown L, et al. (2005) Enumeration and characterization of virus-specific B cells by multicolor flow cytometry. Journal of immunological methods 303: 40–52.
17. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, et al. (2008) Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. Journal of immunology 180: 3279–3288.
18. Hicar MD, Chen X, Briney B, Hammonds J, Wang JJ, et al. (2010) Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J Acquir Immune Defic Syndr 54: 223–235.
19. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, et al. (2008) Arrangement of L2 within the papillomavirus capsid. Journal of virology 82: 5190–5197.
20. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119: 445–462.
21. Crotty S, Aubert RD, Glidewell J, Ahmed R, (2004) Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 286: 111–122.
22. Klein U, Rajewsky K, Kuppers R, (1998) Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 188: 1679–1689.
23. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, et al. (1997) B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 27: 2073–2079.
24. Brochet X, Lefranc MP, Giudicelli V, (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36: W503–508.
25. Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, et al. (2007) Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. Journal of virology 81: 8784–8792.
26. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, et al. (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223: 174–184.
27. Roden RB, Weissinger EM, Henderson DW, Booy F, Kirnbauer R, et al. (1994) Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol 68: 7570–7574.
28. Hicar MD, Kalams SA, Spearman PW, Crowe JE, Jr (2010) Emerging studies of human HIV-specific antibody repertoires. Vaccine 28 Suppl 2: : B18–23.
29. Culp TD, Spatz CM, Reed CA, Christensen ND, (2007) Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361: 435–446.
30. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, et al. (2009) Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog 5: e1000578.
31. Stanley M, Pinto LA, Trimble C, (2012) Human papillomavirus vaccines–immune responses. Vaccine 30 Suppl 5: : F83–87.
32. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, et al. (1996) Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. Journal of virology 70: 3298–3301.
33. Leggat DJ, Thompson RS, Khaskhely NM, Iyer AS, Westerink MA, (2013) The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells. The Journal of infectious diseases 208: 101–108.
34. Franz B, May KF, JrDranoff G, Wucherpfennig K, (2011) Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood 118: 348–357.
35. Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, et al. (2012) Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 30: 3572–3579.
36. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, et al. (2003) Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. Journal of immunological methods 283: 141–153.
37. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633–1637.
38. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, et al. (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109: E3268–3277.
39. Frolich D, Giesecke C, Mei HE, Reiter K, Daridon C, et al. (2010) Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. Journal of immunology 185: 3103–3110.
40. Jiang N, He J, Weinstein JA, Penland L, Sasaki S, et al. (2013) Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med 5: 171ra119.
41. Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, et al. (2012) Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One 7: e33736.
42. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, et al. (2007) Autoreactivity in human IgG+ memory B cells. Immunity 26: 205–213.
43. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.
44. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861.
45. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667–671.
46. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153: 126–138.
47. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, et al. (2012) A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12: 396–407.
48. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593–1602.
49. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, et al. (2004) Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proceedings of the National Academy of Sciences of the United States of America 101: 2706–2711.
50. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The Journal of experimental medicine 208: 181–193.
51. Day PM, Lowy DR, Schiller JT, (2003) Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307: 1–11.
52. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M, (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. Journal of virology 77: 12961–12967.
53. Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ, (2009) Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood 114: 4998–5002.
54. Wismans PJ, van Hattum J, Mudde GC, Endeman HJ, Poel J, et al. (1989) Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 8: 236–240.
55. Lavinder JJ, Wine Y, Giesecke C, Ippolito GC, Horton AP, et al. (2014) Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proceedings of the National Academy of Sciences of the United States of America 111: 2259–2264.
56. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903–1915.
57. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, et al. (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama 309: 1793–1802.
58. Schneider CA, Rasband WS, Eliceiri KW, (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671–675.
59. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D, et al. (2010) Amine-reactive dyes for dead cell discrimination in fixed samples. Curr Protoc Cytom Chapter 9: Unit 9 34.
60. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374–1377.
61. Lebecque SG, Gearhart PJ, (1990) Boundaries of somatic mutation in rearranged immunoglobulin genes: 5′ boundary is near the promoter, and 3′ boundary is approximately 1 kb from V(D)J gene. J Exp Med 172: 1717–1727.
62. Rogerson BJ, (1994) Mapping the upstream boundary of somatic mutations in rearranged immunoglobulin transgenes and endogenous genes. Mol Immunol 31: 83–98.
63. Rada C, Gonzalez-Fernandez A, Jarvis JM, Milstein C, (1994) The 5′ boundary of somatic hypermutation in a V kappa gene is in the leader intron. European journal of immunology 24: 1453–1457.
64. Di Noia JM, Neuberger MS, (2007) Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 76: 1–22.
65. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, et al. (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4: 372–384.
66. Giudicelli V, Duroux P, Ginestoux C, Folch G, Jabado-Michaloud J, et al. (2006) IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic acids research 34: D781–784.
67. Giudicelli V, Chaume D, Lefranc MP, (2005) IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic acids research 33: D256–261.
68. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, et al. (2009) High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 158: 171–179.
69. Wang X, Stollar BD, (2000) Human immunoglobulin variable region gene analysis by single cell RT-PCR. Journal of immunological methods 244: 217–225.
70. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329: 112–124.